¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Coagulation Protein Disorders"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • endolaser coagulation
    ´«¼Ó·¹ÀÌÀúÀÀ°í(¼ú), ¾È³»·¹ÀÌÀúÀÀ°í(¼ú)
  • hereditary coagulation disorder
    À¯ÀüÀÀ°íÀå¾Ö
  • intravascular coagulation
    Ç÷°ü³»ÀÀ°í
  • intrinsic pathway of coagulation
    ³»ÀμºÀÀ°í°æ·Î
  • light coagulation
    ±¤ÀÀ°í
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • antifreeze protein
    Ç×µ¿°á´Ü¹éÁú
  • antiviral protein
    Ç×¹ÙÀÌ·¯½º´Ü¹éÁú
  • adherence protein
    ºÎÂø´Ü¹éÁú
  • androgen binding protein
    ¾Èµå·Î°Õ°áÇմܹéÁú
  • Bence Jones protein
    º¥½º-Á¸½º´Ü¹éÁú
  • coat protein
    ¿ÜÇǴܹéÁú
  • competitive protein binding radioassay
    °æÇմܹéÁú°áÇÕ¹æ»çÃøÁ¤(¹ý)
  • conjugated protein
    Á¢ÇմܹéÁú, °áÇմܹéÁú
  • contractile protein
    ¼öÃà´Ü¹éÁú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intravascular coagulation
    Ç÷°ü³»ÀÀ°í
  • light coagulation
    (¢¡photocoagulation) ±¤ÀÀ°í
  • thermal coagulation
    ¿­ÀÀ°í
  • hereditary coagulation disorder
    À¯ÀüÀÀ°íÀå¾Ö
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • adherence protein
    ºÎÂø´Ü¹é
  • antifreeze protein
    Ç×µ¿°á´Ü¹éÁú
  • protein binding
    ´Ü¹é°áÇÕ
  • carrier protein
    ¿î¹Ý´Ü¹é, ¿î¹Ý´Ü¹éÁú
  • catabolite activating protein
    ÀÌÈ­»ê¹°È°¼ºÈ­´Ü¹é
  • coat protein
    ¿ÜÇǴܹé
  • competitive protein binding radioassay
    °æÇմܹé°áÇÕ¹æ»çÃøÁ¤(¹ý)
  • conjugated protein
    º¹Çմܹé, Á¢ÇմܹéÁú
  • contractile protein
    ¼öÃà´Ü¹éÁú
  • core protein
    Çٽɴܹé
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • AA protein
    ¾Æ¹Ð·ÎÀ̵åA´Ü¹é(¡­Ó±ÛÜ)
  • ABP=> androgen-binding protein
    ¾Èµå·ÎÁ¨°áÇմܹé
  • Bence Jones protein
    º¥½º-Á¸½º´Ü¹é.
  • Bence-Jones protein
    º¥½º-Á¸½º ´Ü¹éÁú
  • C protein
    C´Ü¹éÁú
  • C-Fos protein
    ¾¾-Æ÷½º´Ü¹é(Ó±ÛÜ)
  • C-reative protein =CRP
    C¹ÝÀÀ¼º ´Ü¹é(Áú).
  • C-reative protein =CRP
    [¸é¿ª] [ÀÓº´]C¹ÝÀÀ¼º ´Ü¹éÁú.
  • DNA-binding protein
    DNA °áÇմܹéÁú
  • G protein
    G ´Ü¹é(Ó±ÛÜ)
  • G-myeloma protein
    ¸é¿ª±Û·ÎºÒ¸° G-°ñ¼öÁ¾´Ü¹éÁú
  • Heat shock protein
    ¿­¼ï´Ü¹éÁú
  • Integral membrane protein
    ÅëÇÕ(÷Öùê) ¸·´Ü¹é(Ø­Ó±ÛÜ)
  • M protein
    M´Ü¹éÁú
  • M protein
    M´Ü¹é.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • coagulation factor
    ÀÀ°íÀÎÀÚ
  • coagulation factor deficiency
    ÀÀ°íÀÎÀÚ°áÇÌ
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ ¾ïÁ¦Á¦<¾ïÁ¦ ¹°Áú
  • coagulation factors
    ÀÀ°íÀÎÀÚ(¡­ì×í­)
  • coagulation necrosis
    ÀÀ°í±«»ç(¡­ÎÕÞÝ)
  • coagulation test
    ÀÀ°í½ÃÇè(ëêͳãËúÐ).
  • coagulation time
    ÀÀ°í½Ã°£(¡­ãÁÊà) ¡ìÇ÷¾×ÀÇ¡í.
  • coagulation,disseminated intravascular
    ÆÄÁ¾¼º Ç÷°ü³» ÀÀ°í(÷ëðúàõúìηҮ¡­)
  • coagulation,fibrinolytic system
    ¼¶À¯¼Ò ¿ëÇØ°è(àéë«áÈéÁú°Í§)
  • coagulation,intrinsic pathway
    ³»ºÎ °æ·Î(ҮݻÌèÖØ)
  • diffuse intravascular coagulation
    ¹ü¹ß¼º Ç÷°ü³»ÀÀ°í.
  • disseminated intravascular coagulation
    ÆÄÁ¾¼º Ç÷°ü³»ÀÀ°í(÷ëðúàõúìηҮëêͳ)
  • disseminated intravascular coagulation
    ÆÄÁ¾¼ºÇ÷°ü³»ÀÀ°íÁõ(÷ëðúàõúìηҮëêͳñø)
  • disseminated intravascular coagulation =DIC
    ÆÄÁ¾¼º Ç÷°ü³»ÀÀ°í(?Ì´Ë´ ?ËôË­).
  • disseminated intravascular coagulation =DIC
    ÆÄÁ¾¼º Ç÷°ü³»ÀÀ°í(¡­úìη Ò®ëêͳ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • A protein
    A ´Ü¹éÁú(Ó±ÛÜòõ)
  • azo-dye protein
    ¾ÆÁ¶»ö¼Ò ´Ü¹éÁú(ßäáÈÓ±ÛÜòõ)
  • Bence-Jones protein
    º¥½º-Á¸½º ´Ü¹éÁú(Ó±ÛÜòõ)
  • binding protein
    °áÇմܹéÁú(Ì¿ùêÓ±ÛÜòõ)
  • binding protein transport system
    °áÇÕ ´Ü¹éÁú ¼ö¼Û(Ì¿ùêÓ±ÛÜòõâÃáê) ½Ã½ºÅÛ
  • biotin carboxyl carrier protein
    ¹ÙÀÌ¿Àƾ Ä«¸£º¹½Ç ¿î¹Ý´Ü¹éÁú(ê¡ÚæÓ±ÛÜòõ)
  • blue copper protein
    ûµ¿ ´Ü¹éÁú(ôìÔÞÓ±ÛÜòõ)
  • blue protein
    û´Ü¹éÁú(ôìÓ±ÛÜòõ)
  • B protein
    B ´Ü¹éÁú(Ó±ÛÜòõ)
  • Ca2+-dependent regulatory protein
    Ca2+-ÀÇÁ¸(ëîðí) Á¶Àý´Ü¹éÁú(ðàï½Ó±ÛÜòõ)
  • calcium-dependent regulatory protein
    Ä®½·ÀÇÁ¸ Á¶Àý´Ü¹éÁú(ëîðíðàï½Ó±ÛÜòõ)
  • cAMP-dependent protein kinase
    cAMPÀÇÁ¸(ëîðí) ´Ü¹éÁú(Ó±ÛÜòõ) Ȱ¼ºÈ­È¿¼Ò(üÀàõûùý£áÈ)
  • carboxyl carrier protein
    Ä«¸£º¹½Ç ¿î¹Ý´Ü¹éÁú(ê¡ÚæÓ±ÛÜòõ)
  • carrier protein
    ¿î¹Ýü´Ü¹éÁú(ê¡Úæô÷Ó±ÛÜòõ)
  • catabolite activator protein
    īŸº¼¶óÀÌÆ® Ȱ¼ºÈ­ ´Ü¹éÁú(üÀàõûùÓ±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TRAP carpal tunnel syndrome, Raynaud phenomenon, aching muscles, proximal muscle weakness [rheumatic diso...
DIC Disseminated(=Diffuse) Intravascular Coagulation syndrome; ÆÄÁ¾¼ºÇ÷°ü³»ÀÀ°í(÷ëðúàõúìηҮëêͳ) ÁõÈıº
  = ...
CCF cancer coagulation factor; cardiolipin complement fixation; carotid-cavernous fistula; centrifuged c...
coag coagulation, coagulated
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ILC Interstitial Laser Coagulation
LACI Lipoprotein Associated Coagulation Inhibitor
MCT Microwave coagulation therapy
PMCT Percutaneous microwave coagulation therapy
DIC diffuse intravascular coagulation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • thermal coagulation
    ¿­ ÀÀ°í
  • abnormal protein
    ºñÁ¤»ó ´Ü¹éÁú
  • activated protein C resistance
    Ȱ¼ºÈ­ C ´Ü¹é ³»¼º
  • acute phase protein
    ±Þ¼º±â ´Ü¹éÁú
    °¨¿°À̳ª Á¶Á÷ ¼Õ»óÀÌ ÀÖÀ» ¶§ Á¤»óº¸´Ù 2-100¹è Á¤µµ Áõ°¡ÇÏ´Â Ç÷Àå ´Ü¹éÁúÀ» ÃÑĪÇÏ¿© APP¶ó°í ÇÏ¸ç ¼±Ãµ¼º ¸é¿ª¿¡ °ü¿©ÇÑ´Ù.
  • androgen binding protein
    ³²¼º È£¸£¸ó °áÇÕ ´Ü¹é
  • bacterio protein
    ¼¼±Õ ´Ü¹éÁú
  • body protein
    ü´Ü¹é, ü´Ü¹éÁú
  • C-reactive protein
    C-¹ÝÀÀ ´Ü¹é, C-¹ÝÀÀ¼º ´Ü¹éÁú
  • cellular retinoid acid-binding protein
    ¼¼Æ÷³» ·¹Æ¼³ëÀ̵å»ê °áÇÕ ´Ü¹é
  • chromatographic protein separation
    Å©·Î¸¶Åä±×·¡Çǹý ´Ü¹é ºÐ¸®
  • D-myeloma protein
    D-°ñ¼öÁ¾ ´Ü¹é
    ¸é¿ª ±Û·ÎºÎ¸°ÀÇ ÇÑ ºÎ·ùÀÎ IgD¸¦ »ý»êÇÏ´Â °ñ¼öÁ¾¿¡¼­ ¸¸µé¾îÁø ´Ü¹éÁú.
  • eosinophil protein X
    È£»ê±¸ ´Ü¹é X
  • estrogen receptor protein
    ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ´Ü¹éÁú
  • hapten-protein conjugate
    ÇÕÅÙ ´Ü¹é °áÇÕ¹°
  • heat-aggregated protein
    ¿­ ÀÀÁý ´Ü¹é
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
light coagulation The coagulation of tissue by an intense beam of light, including laser (laser coagulation). In the eye it is used in the treatment of retinal detachments, retinal holes, aneurysms, haemorrhages, and malignant and benign neoplasms.
(12 Dec 1998)
lipoprotein-associated coagulation inhibitor Formerly known as anticonvertin; a protein that inhibits the extrinsic pathway of coagulation by binding to the tissue factor III-factor VII-Calcium-factor Xa complex.
(05 Mar 2000)
lupus coagulation inhibitor An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications.
(12 Dec 1998)
adjustment disorders Maladaptive reactions to identifiable psychosocial stressors occurring within a short time after onset of the stressor. They are manifested by either impairment in social or occupational functioning or by symptoms (depression, anxiety, etc.) that are in excess of a normal and expected reaction to the stressor.
(12 Dec 1998)
affective disorders A class of mental disorder's characterised by a disturbance in mood.
(05 Mar 2000)
affective disorders, psychotic Disorders in which the essential feature is a severe disturbance in mood (depression, anxiety, elation, and excitement) accompanied by psychotic symptoms such as delusions, hallucinations, gross impairment in reality testing, etc.
(12 Dec 1998)
alcohol-related disorders Mental disorders related or resulting from abuse or mis-use of alcohol.
(12 Dec 1998)
amphetamine-related disorders Disorders related or resulting from use of amphetamines.
(12 Dec 1998)
anxiety disorders Disorders in which anxiety (persistent feelings of apprehension, tension, or uneasiness) is the predominant disturbance.
(12 Dec 1998)
articulation disorders Disorders of speech sound production characterised by substitution, omission, and distortion of sounds.
(12 Dec 1998)
auditory perceptual disorders Disorders of auditory perception manifesting as difficulties with auditory memory, speech perception and sound localization. Lesions are usually in the temporal lobe.
(12 Dec 1998)
bowel disorders and fibre High fibre diets help delay the progression of diverticulosis and, at least, reduce the bouts of diverticulitis. In many cases, it helps reduce the symptoms of the Irritable Bowel Syndrome ( IBS ). It is generally accepted that a diet high in fibre is protective, or at least reduces the incidence, of colon polyps and colon cancer.
(12 Dec 1998)
calcium metabolism disorders Disorders in the processing of calcium in the body: its absorption, transport, storage, and utilization.
(12 Dec 1998)
gender identity disorders A class of mental disorders characterised by an incongruity between an assigned culturally determined set of attitudes, behaviour patterns, and physical characteristics associated with masculinity or femininity and gender identity.
See: transsexualism.
(05 Mar 2000)
paranoid disorders Chronic mental disorders in which there has been an insidious development of a permanent and unshakeable delusional system (persecutory delusions or delusions of jealousy), accompanied by preservation of clear and orderly thinking. Emotional responses and behaviour are consistent with the delusional state.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á